Myrobalan Therapeutics
- Biotech or pharma, therapeutic R&D
Massachusetts biotech company develops oral small molecule CNS drugs targeting demyelination and neuroinflammation. Our lead program, MRO-001, a CSF1R inhibitor, aims to be IND-ready by mid-2025 with ALS as the first indication, funded by the ALS Association. Our second lead, MRO-002, a GPR17 antagonist promoting myelin repair, targets neurodegenerative disorders and CNS injuries, with an IND filing anticipated in 2026, supported by the National Multiple Sclerosis Society.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}